System for administering reduced pressure treatment having a manifold with a primary flow passage and a blockage prevention member

Abstract

A reduced pressure delivery system is provided and includes a primary manifold, a blockage prevention member, and first and second conduits in fluid communication with the primary manifold. The primary manifold includes a wall surrounding a primary flow passage and is adapted to be placed in proximity to a tissue site. The blockage prevention member is positioned within the primary flow passage. A plurality of apertures is disposed in the wall to communicate with the primary flow passage. The first conduit is fluidly connected to the primary flow passage to deliver reduced pressure through the primary flow passage and the plurality of apertures. The second conduit includes an outlet proximate the primary flow passage or an outlet of the first conduit to purge the primary flow passage or first conduit to prevent blockages.

1 . A reduced pressure delivery system for applying a reduced pressure tissue treatment to a tissue site comprising: 
 a primary manifold having a wall surrounding a primary flow passage and adapted to be placed in proximity to the tissue site, the wall including an inner surface having a plurality of projections extending from at least a portion of the inner surface and into the primary flow passage, the wall further including a plurality of apertures through the wall and communicating with the primary flow passage;    a first conduit fluidly connected to the primary flow passage to deliver reduced pressure through the primary flow passage and the plurality of apertures; and    a second conduit having at least one outlet in proximity to the primary flow passage or the at least one outlet of the first conduit to purge blockages at or near the at least one outlet of the first conduit.    
   
   
       2 . The system according to  claim 1 , wherein the first and second conduits are part of a multi-lumen tube.  
   
   
       3 . The system according to  claim 2 , wherein the wall and multi-lumen tube are co-extruded.  
   
   
       4 . The system according to  claim 1 , wherein 
 the first and second conduits are part of a multi-lumen tube;    the wall is connected at one end to the multi-lumen tube; and    the primary flow passage is capped at an end of the wall opposite the end connected to the multi-lumen tube.    
   
   
       5 . The system according to  claim 1 , wherein the second conduit is at least partially positioned within the wall.  
   
   
       6 . The system according to  claim 1 , wherein the wall is constructed from at least one of a medical grade silicone polymer, a metal, polyvinylchloride (PVC), polyurethane, and a polymeric material.  
   
   
       7 . The system according to  claim 1 , wherein the wall is substantially rectangular in cross-section.  
   
   
       8 . The system according to  claim 1 , wherein the wall is substantially cylindrical along at least a portion of its axial length.  
   
   
       9 . The system according to  claim 8 , wherein the substantially cylindrical wall subtends an arc of 360 degrees.  
   
   
       10 . The system according to  claim 1 , wherein: 
 the wall is flexible; and    the projections prevent obstruction of the primary flow passage by preventing the flexible wall from fully collapsing during application of reduced pressure through the primary flow passage.    
   
   
       11 . The system according to  claim 1 , wherein the tissue site is comprised of tissue selected from the group of adipose tissue, muscle tissue, neural tissue, dermal tissue, vascular tissue, connective tissue, cartilage, tendons, and ligaments.  
   
   
       12 . The system according to  claim 1  further comprising a secondary manifold adapted to be positioned adjacent the primary manifold and to communicate reduced pressure from the primary manifold to the tissue site.  
   
   
       13 . The system according to  claim 12 , wherein the secondary manifold is bioabsorbable.  
   
   
       14 . The system according to  claim 12 , wherein the secondary manifold is a felted mat.  
   
   
       15 . The system according to  claim 12 , wherein the secondary manifold is a scaffold and is comprised of at least one material selected from the group of polylactic acid, polyglycolic acid, polycaprolactone, polyhydroxybutyrate, polyhydroxyvalerate, polydioxanone, polyorthoesthers, polyphosphazenes, polyurethanes, collagen, hyaluronic acid, chitosan, hydroxyapatite, calcium phosphate, calcium sulfate, calcium carbonate, bioglass, stainless steel, titanium, tantalum, allografts, and autografts.  
   
   
       16 . A reduced pressure delivery system for applying a reduced pressure tissue treatment to a tissue site comprising: 
 a primary manifold having a wall surrounding a primary flow passage and adapted to be placed in proximity to the tissue site, the wall including a plurality of apertures through the wall and communicating with the primary flow passage;    a cellular material positioned within the primary flow passage, the cellular material having a plurality of flow channels;    a first conduit fluidly connected to the primary flow passage to deliver reduced pressure through the primary flow passage, the cellular material, and the plurality of apertures; and    a second conduit having at least one outlet in proximity to the primary flow passage or the at least one outlet of the first conduit to purge blockages at or near the at least one outlet of the first conduit.    
   
   
       17 . The system according to  claim 16 , wherein the first and second conduits are part of a multi-lumen tube.  
   
   
       18 . The system according to  claim 17 , wherein the wall and multi-lumen tube are co-extruded.  
   
   
       19 . The system according to  claim 16 , wherein 
 the first and second conduits are part of a multi-lumen tube;    the wall is connected at one end to the multi-lumen tube; and    the primary flow passage is capped at an end of the wall opposite the end connected to the multi-lumen tube.    
   
   
       20 . The system according to  claim 16 , wherein the second conduit is at least partially positioned within the wall.  
   
   
       21 . The system according to  claim 16 , wherein the wall is constructed from at least one of a medical grade silicone polymer, a metal, polyvinylchloride (PVC), polyurethane, and a polymeric material.  
   
   
       22 . The system according to  claim 16 , wherein the wall is flexible and is reinforced to prevent collapse under reduced pressure.  
   
   
       23 . The system according to  claim 16 , wherein the wall is substantially rectangular in cross-section.  
   
   
       24 . The system according to  claim 16 , wherein the wall is substantially cylindrical along at least a portion of its axial length.  
   
   
       25 . The system according to  claim 24 , wherein the substantially cylindrical wall subtends an arc of 360 degrees.  
   
   
       26 . The system according to  claim 16 , wherein: 
 the wall is flexible; and    the cellular material prevents obstruction of the primary flow passage by preventing the flexible wall from fully collapsing during application of reduced pressure through the primary flow passage.    
   
   
       27 . The system according to  claim 16 , wherein the tissue site is comprised of tissue selected from the group of adipose tissue, muscle tissue, neural tissue, dermal tissue, vascular tissue, connective tissue, cartilage, tendons, and ligaments.  
   
   
       28 . The system according to  claim 16 , wherein the cellular material is a reticulated, polyurethane foam.  
   
   
       29 . The system according to  claim 16  further comprising a secondary manifold adapted to be positioned adjacent the primary manifold and to communicate reduced pressure from the primary manifold to the tissue site.  
   
   
       30 . The system according to  claim 29 , wherein the secondary manifold is bioabsorbable.  
   
   
       31 . The system according to  claim 29 , wherein the secondary manifold is a felted mat.  
   
   
       32 . The system according to  claim 29 , wherein the secondary manifold is a scaffold and is comprised of at least one material selected from the group of polylactic acid, polyglycolic acid, polycaprolactone, polyhydroxybutyrate, polyhydroxyvalerate, polydioxanone, polyorthoesthers, polyphosphazenes, polyurethanes, collagen, hyaluronic acid, chitosan, hydroxyapatite, calcium phosphate, calcium sulfate, calcium carbonate, bioglass, stainless steel, titanium, tantalum, allografts, and autografts.  
   
   
       33 . A reduced pressure delivery system for applying a reduced pressure tissue treatment to a tissue site comprising: 
 a primary manifold having a wall surrounding a primary flow passage and adapted to be placed in proximity to the tissue site, the primary manifold including a blockage prevention member positioned within the primary flow passage, the wall including a plurality of apertures through the wall and communicating with the primary flow passage;    a secondary manifold positioned adjacent the primary manifold and adapted to contact the tissue site such that the secondary manifold fluidly communicates with the primary manifold but is adapted to prevent contact between the primary manifold and the tissue site; and    a first conduit fluidly connected to the primary flow passage to deliver reduced pressure through the primary flow passage and the plurality of apertures.    
   
   
       34 . The system according to  claim 33 , wherein the blockage prevention member is a plurality of projections disposed on an inner surface of the wall and extending into the primary flow passage.  
   
   
       35 . The system according to  claim 33 , wherein the blockage prevention member is a cellular material disposed within the primary flow passage.  
   
   
       36 . The system according to  claim 33 , wherein the secondary manifold is bioabsorbable.  
   
   
       37 . The system according to  claim 33 , wherein the secondary manifold is a felted mat.  
   
   
       38 . The system according to  claim 33 , wherein the secondary manifold is a scaffold and is comprised of at least one material selected from the group of polylactic acid, polyglycolic acid, polycaprolactone, polyhydroxybutyrate, polyhydroxyvalerate, polydioxanone, polyorthoesthers, polyphosphazenes, polyurethanes, collagen, hyaluronic acid, chitosan, hydroxyapatite, calcium phosphate, calcium sulfate, calcium carbonate, bioglass, stainless steel, titanium, tantalum, allografts, and autografts.  
   
   
       39 . A method promoting tissue growth at a tissue site comprising: 
 surgically positioning a primary manifold in proximity to the tissue site, the primary manifold having a wall surrounding a primary flow passage, the wall including a plurality of apertures through the wall and communicating with the primary flow passage, the primary manifold further including a blockage prevention member positioned within the primary flow passage;    surgically positioning a secondary manifold in contact with the tissue site such that the secondary manifold fluidly communicates with the primary manifold but prevents contact between the primary manifold and the tissue site; and    delivering a reduced pressure to the tissue site through the primary flow passage, the plurality of apertures, and the secondary manifold.    
   
   
       40 . The method according to  claim 39 , wherein the blockage prevention member is a cellular material disposed within the primary flow passage, the cellular material having a plurality of flow channels.  
   
   
       41 . The method according to  claim 39 , wherein the blockage prevention member is a plurality of projections extending from an inner surface of the wall and into the primary flow passage.  
   
   
       42 . The system according to  claim 39 , wherein the secondary manifold is a felted mat.  
   
   
       43 . The system according to  claim 39 , wherein the secondary manifold is a scaffold and is comprised of at least one material selected from the group of polylactic acid, polyglycolic acid, polycaprolactone, polyhydroxybutyrate, polyhydroxyvalerate, polydioxanone, polyorthoesthers, polyphosphazenes, polyurethanes, collagen, hyaluronic acid, chitosan, hydroxyapatite, calcium phosphate, calcium sulfate, calcium carbonate, bioglass, stainless steel, titanium, tantalum, allografts, and autografts.  
   
   
       44 . The method according to  claim 39  further comprising: 
 percutaneously removing the primary manifold following completion of reduced pressure tissue treatment.    
   
   
       45 . The method according to  claim 39  further comprising: 
 percutaneously removing the primary manifold following completion of reduced pressure tissue treatment; and    wherein the secondary manifold is bioabsorbable.    
   
   
       46 . The method according to  claim 39  further comprising purging the primary flow passage with ambient air to prevent blockages within the primary flow passage.